| Barchart Demo Center |
$1.01
-0.07 (-6.48%)
as of Jun 14, 2019
as of Jun 14, 2019
| Last | 1.01 |
|---|---|
| Change | -0.07 (-6.48%) |
| Open | 1.07 |
| Prev. Close | 1.08 |
| Today's Range |
1.01
1.08
|
| 52wk Range |
0.66
12.15
|
| Volume | 702,600 |
| Avg Volume | 10,053,030 |
| Sector | SIC-8071 Services-Medical Laboratories |
Perfomance Comparison
| Name | Today | 3-Month | 1-Year |
|---|---|---|---|
| BIOC |
 -6.48% |
 -7.34% |
-85.97% |
| DJIA |
-0.07% |
-0.49% |
 +3.63% |
| S&P 500 |
-0.16% |
+0.47% |
 +3.76% |
Key Statistics
| Annual EPS | -7.16 |
|---|---|
| Dividend Yield | 0.00% |
| P/E Ratio | N/A |
| Market Capitalization, $K | 20,380 |
| Weighted Alpha | -89.80 |
| Standard Deviation | -0.41 |
| Profit Margin | 3.63% |
| Beta | 2.17 |
Growth Rates
| YTD | +17.44% | |||
| 1-Year | -87.05% | |||
| 3-Year | -98.19% | |||
| 5-Year | -99.85% |
Opinion
| Sell | Hold | Buy |
Recent Headlines
Biocept Announces Clinical Validation and Commercial
PR Newswire via COMTEX - Mon May 20, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the comm(full story)
BIOC: 1.01 (-0.07)
Biocept Reports First Quarter 2019 Financial Results
PR Newswire via COMTEX - Wed May 08, 04:05PM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the(full story)
BIOC: 1.01 (-0.07)
Biocept to Release First Quarter 2019 Financial
PR Newswire via COMTEX - Wed May 01, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve the outcomes of patients diagnose(full story)
BIOC: 1.01 (-0.07)
Biocept Reports 2018 Fourth Quarter and Full Year
PR Newswire via COMTEX - Thu Mar 28, 04:05PM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the(full story)
BIOC: 1.01 (-0.07)
Biocept Broadens Commercial Focus of its Target
PR Newswire via COMTEX - Tue Mar 26, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it (full story)
BIOC: 1.01 (-0.07)